Drug intelligence / Profile preview

33525

Development stage: Preclinical
Lead developer: Valeant Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

33525 is a topical antifungal cream developed by Medicis Global Service Corporation. It is being investigated for its safety and efficacy in the treatment of tinea pedis (athlete's foot) and tinea cruris (jock itch).

Other names: Product 33525Product33525Product-33525

Targets

CYP3A4 (Cytochrome P450 3A4)CYP51A1 (Sterol 14α-demethylase)CYP2C19 (Cytochrome P450 2C19)

Beyond the preview

Go deeper on 33525.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 33525.

Explore the full profile